 |
市場調查報告書
擴大性心肌病治療藥的全球市場 (2020∼2027年)Global Dilated Cardiomyopathy Therapeutics Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 955330 | ||||
| 出版日期 | 內容資訊 | 英文 商品交期: 最快1-2個工作天內 |
|||||
| 價格 |
|
||||||
| 擴大性心肌病治療藥的全球市場 (2020∼2027年) Global Dilated Cardiomyopathy Therapeutics Market - 2020-2027 | ||
| 出版日期: 2020年08月27日 | 內容資訊: 英文 |
|
本報告提供全球擴大性心肌病的市場相關分析，市場基本結構及最新形勢，整體市場趨勢預測 (今後8年份)，各藥物類別、各流通管道及各地區詳細趨勢，主要的推動及阻礙市場要素，市場競爭結構，主要企業的簡介、事業策略等相關調查。
The global dilated cardiomyopathy therapeutics market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contribute to irregular heartbeats (arrhythmias), blood clots or sudden death. People of all ages are affected by DCM, including infants and children, but is most common in men ages 20 to 50.
The global dilated cardiomyopathy therapeutics market growth is majorly driven by the rising prevalence of heart problems, increasing number of people suffering from cardiac muscle infections, and the drug or alcohol abuse. Cardiovascular disease (CVD) is a major cause of death in the United States, responsible for 840,768 deaths (635,260 cardiac) in 2016. From 2006 to 2016, the US death rate from CVD declined by 18.6% and from coronary heart disease by 31.8%.
According to the World Health Organization (WHO), there were 17.5 million deaths in 2013 were related to heart disorders. Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.
With the rising demand for therapeutic treatment of dilated cardiomyopathy, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy. There is no specific FDA approved drug for dilated cardiomyopathy because of which the treatment administered is the same as that for congestive heart failure.
In February 2020, a Keio University research team has been given the green light for transplant heart muscle cells derived from iPS cells into patients who have experienced severe heart failure. The study aims to conduct the study by the end of 2020 and targets patients with dilated cardiomyopathy, which lowers the systolic function of heart muscle cells.
Hence, the success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market over the forecast period (2020-2027).
MyoKardia's aim is to develop drugs for genetically defined patient groups, which is also reflected in its second program, MYK-491, under development for dilated cardiomyopathy. The Sanofi has a partnership in 2014 involved in the development of three programs through discovery and into clinical development for the treatment of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). However, in January 2019, MyoKardia had regained the global rights to all the programs (including mavacamten and MYK-491) under the research and collaboration agreement with Sanofi, will not be extended beyond the initial research term, which ended on December 31, 2018. As part of the deal, MyoKardia received roughly $230 million funding from Sanofi and has advanced mavacamten from the preclinical development into a late-stage pivotal study for the treatment of HCM, and MYK-491 from discovery to a Phase II proof-of-concept study in patients with DCM.
The severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) is emerging as a global threat due to the high transmission rate of the virus. Patients with pre-existing cardiovascular diseases may favour more severe clinical manifestations, and conversely, SARS-CoV-2 may cause myocardial injury. The exponential need for hospitalization and intensive care due to COVID-19 infections thoroughly changed the priorities of healthcare systems globally. Hospitals were in part or completely dedicated to Covid-19 patients, and therefore, routine management of patients with inherited channelopathies and cardiomyopathies was suspended in most hospitals.
However, the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market. Moreover, the availability of implantable devices and promising gene therapy are acting as roadblocks to the market.
On the basis of drug class, the dilated cardiomyopathy therapeutics market is segmented by drug class into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers, and others. Among these, the angiotensin II receptor blockers drug class is estimated to account for the largest market share, owing to the rising demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions.
On the other hand, the aldosterone antagonists is expected to grow at the highest CAGR over the forecast period, due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which in turn would positively impact market growth. According to some studies, the angiotensin receptor blockers such as valsartan can reduce the probability of hospitalization by 28%. These drugs are also effective for patients of systolic heart disease by reducing the deaths by 37% and also for reducing the frequency of hospitalization. Common anti-arrhythmia medications include amiodarone, procainamide, and lidocaine. Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker which reduces the spontaneous pacemaker activity of the cardiac sinus node. The US FDA approval of Corlanor (ivabradine) for the treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years was based on a randomized, double-blind, placebo-controlled trial in 116 patients aged 6 months to less than 18 years with symptomatic DCM in sinus rhythm, NYHA/Ross class II to IV HF, and left ventricular ejection fraction ≤45%. The primary endpoint of the study was ≥ 20% reduction in resting heart rate from baseline without bradycardia or symptoms after an initial titration period.
Geographical Analysis
North America region is dominating the global dilated cardiomyopathy therapeutics market accounting for the largest market share in 2019, owing to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors. The annual total cost of CVD in the United States was estimated at $351.2 billion in 2014-2015, with $213.8 billion in direct cost, including 46% for inpatient care. In this region, the United States holds the largest market share due to factors such as rising geriatric populations, an increasing number of heart diseases in the country, which boosts the demand in this region. Hence, as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.
In addition, the market players are investing in research and development to conduct the trials for new treatment drugs dor dilated cardiomyopathy. For instance, in July 2019, Recursion Pharmaceuticals, which uses artificial intelligence to discover drugs, has raised $121 million in a round led by Baillie Gifford. The company is a new drug discovery start-up to raise funds in 2018, as investors flock to the sector hoping that the costly and cumbersome process of finding a drug will be transformed by techniques such as computer vision and machine learning. Recursion is trying to make its own drugs for rare diseases, as well as partnering with major pharmaceutical companies such as Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma companies in areas such as oncology and inflammation.
Competitive Landscape
The dilated cardiomyopathy therapeutics market is moderately competitive with several major players including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer Inc., t2cure GmbH, MyoKardia, Kasiak Research pvt. Ltd., among others
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the dilated cardiomyopathy therapeutics market globally. For instance,
The global dilated cardiomyopathy therapeutics market report would provide an access to an approx. 44 market data table, 41 figures and 220 pages.
Target Audience
LIST NOT EXHAUSTIVE
